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Background: The burden of symptoms and other concerns in chronic kidney disease (CKD) is known 
to be high, adversely affecting the quality of life of the growing number of those with this condition in 
developing countries. In this paper, we describe the protocol of a longitudinal observational study among 
people living with CKD. The study is developed to assess the bio-psychosocial factors associated with 
palliative care symptoms and concerns, and pattern of health services usage among Nigerians with stages  
3–5 CKD. The overall objective is to establish the evidence-base for advocacy and policy formulation, 
treatment guidelines, care and services, and future clinical trial studies.
Methods: This is a multi-center study to investigate the longitudinal course of symptoms and other 
concerns among patients with stages 3–5 CKD in Nigeria. Interviewer administered and self-report 
measures at baseline (T0) and 3-month (T1) address socio-demographic characteristics, clinical-illness 
related information, palliative care-related symptoms and other concerns, pattern of formal or informal 
service usage, and bio psychosocial measures including estimated glomerular filtration rate (eGFR), anxiety, 
depression, quality of life, functioning, social support and spiritual wellbeing.
Discussion: This study represents the first longitudinal investigation of palliative care symptoms and 
concerns among people with CKD in Nigeria. It includes early stages of CKD in compliance with best 
practices, and a comprehensive range of bio-psychosocial outcomes to understand how these factors are 
associated with symptoms. This study will provide evidence for how best to integrate palliative care into 
management of CKD to improve care and quality of life of people with CKD. The study team welcomes 
collaborations with both national and international researchers.
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Introduction
There is a growing concern about the increasing burden of 
life-threatening conditions and the lack of services to address 
the needs of those affected in developing countries (1). 
In 2015, about 35.5 million people experienced serious 
health-related suffering due to life-threatening and life-
limiting conditions. A disproportionate number (more 
than 80%) of these individuals live in low-income and 
middle-income countries with severely limited access to any 
palliative care (2).
Chronic kidney disease (CKD) (defined with an 
estimated glomerular filtration rate (eGFR) of less than 
60 mL/min) is a life-threatening condition of particular 
concern because of the worsening trend in its prevalence. 
For instance, the prevalence of CKD in Nigeria is 12.1% (3), 
and similar to a pooled prevalence rate of 13.9% reported 
in a meta-analysis of 21 sub-Saharan African (SSA) studies 
(4,5). Future estimates project an exponential increase in the 
burden of CKD, and that developing countries will account 
for up to 70% of people with CKD worldwide by 2030 (6). 
An increase in the burden and service needs of people with 
CKD in SSA also seems inevitable given a projection of up 
to 130% increase in the prevalence of diabetes mellitus and 
hypertension, (two leading contributors to CKD burden) 
in Africa by the year 2020 (7). Beyond impacting on dialysis 
and renal replacement services, increasing prevalence of 
CKD may significantly increase the need for palliative care. 
This is due to disease progression, deterioration in organ 
function, accumulation of toxic products, high symptom 
load, co-morbidity of other life-threatening illnesses, and 
high mortality, thereby necessitating end of life-care (8,9).
Palliative care is defined as an approach that improves 
the quality of life of patients and their families facing life-
threatening illness (1). The current evidence highlights the 
growing need for physicians to pay attention to the palliative 
or end-of-life care needs of patients with CKD as they have 
a shortened life expectancy (10,11). This is because patients 
with CKD often experience high symptom burden (10) 
including pain, fatigue, itching and sleep problems, all 
contributing to an overall negative impact on the patients’ 
quality of life (QoL) (12). To this end, the American Society 
of Nephrologists recommended integration of palliative 
care into treatment of patients with CKD (13). 
Several factors are thought to drive the increasing burden 
of CKD as well as existing gaps in palliative care services. 
Such factors include high prevalence of chronic illnesses, 
absence of kidney disease prevention programs, inequitable 
distribution of resources, low literacy, late presentation and 
lack of governmental funding necessitating out-of-pocket 
payments among others (14-16). In addition to these factors, 
both psychosocial and biomedical factors often impact 
treatment decision, the course of the illness, palliative care 
needs, and quality of life in CKD (16,17). Previous studies 
have reported high rates of a range of psychosocial factors, 
including anxiety, depressive disorders, poor social support 
and suicidality among patients with CKD (18), with rates 
of depression and anxiety symptomatology reaching up to 
33.4% (16,19,20). These psychosocial factors often have far 
reaching adverse consequences on patients’ function, illness 
course, outcome and palliative care needs (16,21-23). In line 
with the World Health Organisation definition, we need all 
these dimensions to be measured to truly understand the 
extent of need (1).
The extent of palliative care needs and the specific 
roles of biopsychosocial factors (including social support, 
diet, hypertension, and diabetes mellitus among other) 
on CKD in SSA are largely unknown because evidence is 
scarce (24,25). The extrapolation of findings from existing 
literature to SSA population is limited because these studies 
were mostly from developed countries and focused on 
advanced CKD. Again, access to palliative care services 
and available resources in SSA are very poor (2) despite the 
call for palliative care for all in the new universal health 
coverage goals (26). Hence more data from valid measures 
are needed to understand palliative care-related problems, 
design policy and plan palliative care services in line with 
the recent World Health Assembly resolution on palliative 
care (27). There is also a need for broader inclusion of early 
stages of CKD as proposed in this study to enhance early 
integration of palliative care as recommended by the World 
Health Organization. Despite the weight of evidence, 
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there is lack of focus on palliative care in the global health 
literature and more research is needed to underpin public 
health approaches to expansion in SSA (28,29). In light 
of the above, this longitudinal study aims to measure the 
prevalence and bio-psychosocial factors associated with 
palliative care symptoms and concerns among people 
diagnosed with stages 3–5 CKD. The specific objectives are:
(I) To measure the prevalence of symptoms and other 
concerns;
(II) To identify the bio-psychosocial factors associated 
with palliative care-related symptoms concerns 
among people with stages 3–5 CKD;
(III) To determine whether there is change in outcomes 
over a 3-month period;
(IV) To measure the use and identify predictors of 
formal and informal healthcare services during this 
time. 
Methods
Study design and setting
This is a multi-centre longitudinal observational study 
among people diagnosed with CKD, collecting self-
report data at baseline (T0) and 3-month follow-up in the 
renal outpatient clinics of two tertiary teaching hospitals 
in Lagos, Nigeria. These study centres are government-
funded hospitals within Lagos State which has a population 
of about 20 million people. The hospitals also serve people 
from neighbouring states, other parts of Nigeria and nearby 
African countries. The two hospitals have nephrology units 
under their respective medical departments with facilities 
for renal replacement therapy (RRT) including renal 
dialysis. 
Study participants
Inclusion and exclusion criteria: The eligibility criteria 
include adults 18 years and above with confirmed diagnosis 
of stages 3–5 CKD base on eGFR of <60 mL/min (30). The 
diagnosis of CKD is made by consultant Nephrologists (in 
centres where study is ongoing) based on evidence of kidney 
damage for at least 3 months and/or glomerular filtration 
rate (GFR) less than 60 mL/min/1.73 m2 for at least 
3 months with or without kidney damage (31). Those 
deemed by their treating clinicians to be too unwell to 
participate in a research interview with study instruments 
were excluded from recruitment.
Sample size calculation
We determined the sample size to estimate prevalence 
of palliative care symptoms and concerns among people 
with stages 3–5 CKD. This gave the largest sample size 
estimate and adequate to meet the other study objectives. 
The margin of error was set at 0.5%, the confidence 
interval was set at 95%, and response distribution was set 
at 50% (32). The population size was derived from the 
average number of new patients with CKD seen in the 
study sites annually, which is estimated from clinic records 
as n=520. Of these, half or lesser are diagnosed with stage 
3–5 CKD among the new patients. Thus, an estimated 
sample size of 156 participants was derived, and we aim 
to recruit additional 20% to allow for attrition during 
follow-up resulting in sample size of 187 participants. 
We consider the sample size (n=187) ideal as it is larger 
than the estimate derived from other study objectives. For 
instance, a sample size of 100 was needed to detect small 
effect size of 0.3 (8) for change in palliative care concerns 
of people with stage 3–5 CKD over a 3-month period 
(objective 3) with alpha =0.05, power =0.95, one group and 
two data point measure using repeated measure ANOVA 
for within group comparison (33). 
Data collection
A single pack containing the tools for data collection is 
created for baseline (T0) and another set for follow-up at 
3-month (T1) for each patient. The pages are colour coded 
by time point, and preceded by a log page to complete 
the interview dates and a front cover with the patient’s ID 
number. Data is collected at baseline with all the tools and 
subsequently a repeat follow-up assessment at 3 months 
excluding the demographic chart (see Table 1). A flexibility 
of 4 weeks before and after 3 months for the second data 
collection is allowed. This is to accommodate rescheduling 
of participants 3 months appointments. The follow-up 
data collection at 3 months is set to coincide with the 
3-monthly schedule of follow-up appointments in the study 
centres. To reduce follow-up attrition, respondents are 
sent text messages 1 month after the baseline assessment to 
remind them of the study and confirm date for follow-up 
appointment. Additionally, participants are rung to remind 
them of the follow up data collection appointment. In cases 
of loss to follow-up, reasons for attrition are documented 
if known to the researcher. This information will help to 
estimate response rate at the end of the project. 
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Data are collected by trained research assistants. The study 
participants are recruited consecutively from the outpatient 
clinics and data collection are supervised by the investigators. 
While some of the measures are self-reported, others are 
interviewer administered according to standard described in 
the original scales. The study participants are interviewed 
in separate consulting room to ensure confidentiality of 
responses. All questionnaire is de-identified and locked up 
in a safe cabinet where only the principal investigators have 
access after completion of data collection. 
Ethical approval
The study protocol was approved by the Health and 
Research Ethical Committee of the Lagos University 
Teaching Hospital (approval number: ADM/DCST/HREC/
APP/1953), Lagos State University Teaching Hospital 
(approval number: LREC./10/1001) and Kings College 
London (approval number: HR-17/18-5413). All eligible 
participants were explained all study details in writing and 
in person before giving informed consent. Participants 
are enrolled and interviewed following written informed 
consent is obtained. Data are stored in a research database 
in accordance with the Standard Protection Authority.
Study instruments 
Assessments are done at baseline and a follow-up at 
3 months using the following interviewer administered and 
self-report measures. 
The interviewer administered measures include: 
(I) Study-specific questionnaire: this was designed to 
elicit socio demographic data including age, gender, 
employment status, occupation, religion, ethnicity, 
level of education, and marital status. In addition, 
clinical history is elicited from patients and their 
clinical records on a range of variables including 
duration of CKD/illness, etiological risk of CKD 
(including hypertension, and diabetes mellitus), 
average number of dialysis, co-morbidities, reasons 
why they have not had a renal transplant, past 
personal and history of emotional problems in family 
members. Some important clinical variables such as 
medication use, the average sessions of dialysis per 
week are extracted from patient’s case notes. Other 
clinical/biomedical variables are derived from results 
of standardized investigations or measurement 
carried out. Some of these variables include body 
mass index (BMI), fasting blood sugar/2-hour post 
prandial, urinalysis, blood pressure, E/UR/Cr, and 
the primary cause of disease is extracted from the 
case note if documented. 
(II) Australia-modified Karnosky Performance Status 
(AKPS): the AKPS was designed as a useful 
modification of the Karnofsky Performance Status 
(KPS) by combining the KPS which is the gold 
standard in measurement of functioning in clinical 
settings and the Thorne-modified KPS (TKPS) 
which is focuses on community-based care. The 
Table 1 Study plan and assessment
Variables/
assessed items 
Baseline
3-month 
follow-up
Measures and instruments
Demographics x – Age, gender, ethnicity, 
marital status, employment, 
education, religion, income, 
and living arrangement
Illness 
characteristic
x x Dialysis, history of kidney 
transplant, duration of CKD 
Clinico-
anthropometric
x x Causes of CKD, comorbid 
condition, eGFR, weight, 
height and blood pressure
Biological 
factors
x x Level of creatinine, urea, 
hemoglobin, sodium, 
potassium, bicarbonate, 
chloride
Psychological 
factors
x x GAD-7, PHQ-9,
Social factors x x MSPSS
Quality of life x x EQ5D-5L
Functioning x x AKPS
Symptoms 
profile
x x African IPOS
Palliative 
concerns
x x Palliative Client Service 
Receipt Inventory
Spiritual 
wellbeing
x x Spirit 8
Service usage x x CSRI Palliative Client 
Service Receipt Inventory
CKD, chronic kidney disease; eGFR, estimated glomerular 
filtration rate; GAD-7, General Anxiety Disorders-7; PHQ-9, 
Patient Health Questionnaire; MSPSS, multidimensional Scale 
of Perceived Social Support; EQ5D-5L, EuroQol five dimensions 
five levels questionnaire; AKPS, Australia-modified Karnosky 
Performance Status; IPOS, Integrated Palliative care Outcome 
Scale; CSRI, Client Service Receipt Inventory.
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AKPS was designed as a measure considered to 
be more appropriate for any care setting and 
especially in outpatient populations (34). It is a 
measure of the patient’s overall performance status 
or ability to perform their activities of daily living. 
It is an ordered categorical scale with 11 levels and 
scores are assigned in increments of 10 between 
0 and 100. The scores are assigned by a clinician 
based on observations of a patient’s ability to 
perform common tasks relating to activity, work 
and self-care and in between scores (e.g., 35) are 
invalid. Decreasing numbers indicate a reduced 
performance status. A score of 100 signifies normal 
physical abilities with no evidence of disease, while 
a score of 0 refers to a dead/deceased patient. It can 
be completed in less than 2 minutes (35).
(III) The African Palliative Care Association (APCA) 
African Palliative Outcome Scale (APOS): the 
APOS is an interviewer administered instrument 
that  was designed using/adapted from the 
Integrated Palliative care Outcome Scale (IPOS) 
for use among Africans (36). It was developed for 
use in patients with life threatening conditions to 
improve outcome by assessing the full range of 
needs of patients with life-threatening conditions, 
thereby ensuring that patients and family caregivers 
get the best possible care. It contains ten questions 
on physical and psychological symptoms, spiritual, 
practical and emotional concerns and psychosocial 
needs of the patient and their relatives. The first 
seven questions concern the patients while the 
remaining three questions are directed at family 
and other informal caregivers. It has been used 
mainly in east and Southern African countries 
including Botswana, Kenya, Malawi, South Africa, 
Tanzania, Uganda, Zambia and Zimbabwe (37). 
The scale is simple to administer, Cronbach’s 
Alpha was 0.6 indicating expected moderate 
internal consistency; test-retest found high intra-
class correlation coefficients for all items (0.78–
0.89), and can be completed within an average 
time of 8 to 9 minutes (37).
(IV) Client Service Receipt Inventory (CSRI): the 
CSRI was designed about three decades ago to 
collect information on service utilisation, income, 
accommodation and other cost-related variables. 
There have been several versions designed for use 
in various patient/client populations including 
Generic mental health CSRI, chronic pain CSRI, 
Arthritis study CSRI and Homestart CSRI among 
others (38). For this study, we adapted the modified 
Palliative version CSRI questionnaire, which has 
been adapted for African population (39). 
(V) Spirit-8: the Spirit 8 was designed to measure 
spiritual well-being (SWB) among palliative care 
patients in SSA as a means to improve spiritual 
care (40). It was developed from the Missoula Vitas 
Quality of Life Index (MVQOLI), a tool created in 
the USA (41). The scale composes of eight items 
that are scored on a 5-point Likert scale from 1 
(worst) to 5 (best). The instrument is interpreted 
by summing the individual scores from all the 8 
items resulting in a possible score of between 8 and 
40 with higher scores indicating a better outcome. 
It has been used in African populations and shown 
to have good internal consistency (Cronbach’s 
alpha =0.73) (40).
The self-reported measures include:
(I) Patient Health Questionnaire (PHQ-9): the Patient 
Health Questionnaire (PHQ-9) is used in this study 
to screen for depression. It is a 9-item self-report 
questionnaire that efficiently establishes DSM-IV 
criteria based psychiatric diagnoses (42). PHQ-9 is 
a validated and shown to have good psychometric 
properties (internal consistency =0.85 and test-
retest reliability, r=0.894, P<0.001). Respondents 
are required to rate how they feel in the preceding 
2 weeks. Each question is scored 0 to 3 (0 = not at 
all, 1 = several days, 2 = more than half the days 
and 3 = early everyday) with a resulting range of 
0 to 27. The cut-off scores of 5, 10 and 15 are 
suggestive of mild, moderate and severe depression 
respectively (42,43). Adewuya et al. (43) reported 
that a cut-off of 5 or higher provides a sensitivity 
of 89% and specificity of 98% among Nigerian 
university students.
(II) General Anxiety Disorders-7 (GAD-7): the GAD-
7 is a 7-item questionnaire developed to identify 
cases of GAD and measure the severity of GAD 
symptoms (44). The GAD-7 asks participants to 
rate how often they have been bothered by each of 
the 7 core symptoms included in the questionnaire 
over the preceding 2 weeks. Response categories 
include “not at all”, “several days”, “more than half 
the days”, and “nearly every day”, scored as 0, 1, 
2, and 3, respectively with the total score ranging 
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from zero to 21. A cut-off score of 10 or higher 
(recommended cut off score) provides a sensitivity 
of 89% and a specificity of 82% for GAD (45).
(III) Multidimensional Scale of Perceived Social 
Support (MSPSS): the MSPSS is used to measure 
perceived social support in this study (46). It is a 
12-item instrument that provides assessment of 
three sources of support: family support, friends 
support, and significant others support. It is scored 
on a 5-point Likert scale with scores ranging from 
1 “strongly disagree” to 5 “strongly agree”. Items 
3, 4, 8 and 11 measure family support; items 6, 7, 
9 and 12 measures friend support while items 1, 2, 
5, and 10 measures significant other support. It has 
been shown to have good psychometric properties 
with a Cronbach’s alpha of 0.82 and well used in 
previous studies in this environment (47-49).
(IV) EuroQol five dimensions five levels questionnaire 
(EQ5D-5L): the EQ-5D (50) is a disease non-
specific (generic) instrument that measures quality 
of life across several cultural setting and validated in 
African population (51). The EQ-5D is brief, with 
five questions that bother on mobility, self-care, 
pain, usual activities and psychological status as 
well as a visual analogue scale which asks patients to 
state their opinion of their state of health as of the 
day of assessment ranging from 0 (worst imaginable 
state) to 100 (best imaginable). EQ5D-5L which 
has five levels of severity (no problems, slight 
problems, moderate problems, severe problems, 
and extreme problems). The EQ5D-5L is used in 
this study because of its superior discriminating 
effects compared to the EQ5D-3L among patients 
with other chronic medical conditions (52).
Data analyses plan
The study data are longitudinal quantitative in nature, and 
will be entered into predesigned Excel spreadsheets. This 
will be exported to IBM-SPSS-22 for analysis, including 
creation of graphs, descriptive statistics, univariate analysis 
and multiple regression.
The primary outcomes (dependent variables) including 
palliative care-related symptoms and concerns, spiritual 
wellbeing and quality of life are the summary scores derived 
from APOS, AKPS; EQ-5D and spirit-8 respectively. The 
secondary measures of interest [independent variables] 
include psychosocial factors (such as anxiety, depression, 
and social support) and biomedical factors including levels 
of electrolyte, creatinine and urea, eGFR, blood pressure, 
blood sugar level, and BMI. Analyses plans for the main 
study objectives are outlined below.
Study objective 1: assess the prevalence of symptoms 
and other concerns among people with stages 3–5 CKD 
Socio demographic, baseline clinical characteristics, 
prevalence and distribution of scores on palliative 
care symptoms and concerns will be summarized with 
descriptive statistics using frequencies, means (SD) and 
percentages after testing for normality. Non-parametric 
data will be summarized with median and interquartile 
range. A P value of 0.05 will be used to determine 
significance in all statistical tests except for the decision 
to include variables in multivariate analysis, when 0.1 will 
be used. For univariate analysis of demographic/clinical 
characteristics with primary outcomes at baseline, ANOVA 
will be used for ordinal variables and linear regression for 
continuous.
Study objective 2: determine the bio-psychosocial 
factors associated with symptoms and other concerns 
among people with stages 3–5 CKD
Regression analysis will be conducted to investigate whether 
or not bio-psychosocial factors predict the experience of 
symptoms and concerns among participants following 
univariate correlation analyses. For regression analyses, 
the relationship of each primary outcome (palliative care 
symptoms/concerns, spiritual wellbeing and quality of life) 
will be explored with the secondary measures of interest 
including psychosocial factors (such as anxiety, depression, 
and social support), and biomedical factors (including 
electrolytes, creatinine and urea, eGFR, blood pressure, 
blood sugar, and BMI) extracted from the case notes.
Study objective 3: investigate any change in the 
symptoms and other concerns of people with stages 3–5 
CKD over a 3-month period
Changes in symptoms and other concerns over a 3-month 
period are analysed using repeated measure ANOVA. 
Longitudinal multilevel modelling is an approach which 
makes the most efficient use of data collected over time. 
Thus, longitudinal multilevel modelling will be conducted 
to evaluate the contribution of biopsychosocial variables 
to the variance of change in palliative care symptoms, 
concerns, spiritual wellbeing and quality of life over the two 
data points (baseline to follow up at 3 months).  
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Study objective 4: assess the use of formal and informal 
healthcare services during this time
The components of care recorded in the CSRI will be 
grouped into care themes according to the issues they 
address and the way in which they are delivered. Descriptive 
statistics is used to summarize the use of formal and informal 
healthcare services. Univariate-correlation analyses will be 
performed to investigate the relationship between health care 
service usage and sociodemographic and clinical factors. 
Discussion
This is the first study to investigate symptoms and other 
concerns among people with stages 3–5 CKD in Africa 
despite indications for palliative care services in CKD. 
We believe there are several elements in the design and 
implementation of this study that allow advantages for 
quality data to inform the care of CKD in SSA. 
First, this study will provide substantive data in a 
neglected region on the symptom burden and services 
in CKD, in order to improve care for people with CKD. 
Our goal is early integration of palliative care services into 
management of CKD and to direct future clinical studies. 
Second, the study will generate health outcome and cost 
data that is Africa-specific and multidimensional in line 
with the palliative care definition and advancing knowledge 
beyond what is known already. Third, findings from this 
work can inform stakeholders and guide policy to design 
palliative care services to support patients with CKD. 
By extension, findings from this study may be beneficial 
to patients with other life-threatening conditions, and 
influence incorporation of palliative care training for 
professionals involved in the care of patients with CKD and 
other life-threatening conditions. We plan to use data from 
this study to drive advocacy for evidence-based interventions 
to mitigate the burden of CKD and advance the global 
science of conservative management of CKD in SSA. To 
enhance translation, study findings will be disseminated 
in peer reviewed journal and presentations in conferences 
and meetings. Fourth, the staffs working on the project are 
indigenous African researchers, and considerable capacity 
has been built through ongoing training and the conduct of 
this multisite study. In addition, the nature of this project 
can promote intentional collaboration between African and 
UK expertise for future multi-national studies. Lastly, the 
novel method in this study brings together an integrated 
mixture of outcome measurement, biopsychosocial factors, 
longitudinal evaluation, health economics and service usage 
to evaluate palliative concerns in CKD. 
The careful attention to multi-professional inclusivity and 
consultation has maximised the feasibility of this study where 
many logistical challenges are possible. We believe that the 
presentation of this protocol offers greater transparency in 
the aims, objectives and analysis of our study, and will allow 
greater quality reporting of our large dataset. 
In conclusion, this study is a novel approach utilizing 
relevant measures to collect comprehensive clinical, 
b iologica l  and psychosocia l  data  to  improve the 
understanding of CKD in relation to patients and caregiver’s 
experiences, their symptom and other concerns and service 
usage. The BUILD care team welcomes collaborations with 
both national and international investigators.
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